ARTICLE | Company News
Ark Biosciences Inc. (Shanghai, China) gained exclusive, worldwide rights from Roche (SIX:ROG; OTCQX:RHHBY) to develop and commercialize AK3280 (GDC3280) to treat idiopathic pulmonary fibrosis.
Roche is eligible to receive milestone payments and royalties and will retain certain preferential rights. The partners declined to provide details...